About Gap junction gamma-1 protein
Gap junction gamma-1 protein (GJC1) is a protein
from Homo sapiens identified by UniProt accession
P36383, 396 residues long.
MolForge cross-references it against 0 known binders and
146 disease associations.
Target properties
| Protein name | Gap junction gamma-1 protein |
| UniProt accession | P36383 |
| Gene | GJC1 |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (146)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.36
- self reported educational attainment · score 0.27
- male reproductive organ cancer · score 0.25
- platelet component distribution width · score 0.20
- cognitive function measurement · score 0.19
- systolic blood pressure · score 0.16
- lung adenocarcinoma · score 0.14
- hypertrophic cardiomyopathy · score 0.06
- left ventricular noncompaction · score 0.06
- congenital heart disease · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P36383-F1 | alphafold | PREDICTED | 69.45 | — |
Amino-acid sequence (396 residues)
MSWSFLTRLL EEIHNHSTFV GKIWLTVLIV FRIVLTAVGG ESIYYDEQSK FVCNTEQPGC ENVCYDAFAP LSHVRFWVFQ IILVATPSVM YLGYAIHKIA KMEHGEADKK AARSKPYAMR WKQHRALEET EEDNEEDPMM YPEMELESDK ENKEQSQPKP KHDGRRRIRE DGLMKIYVLQ LLARTVFEVG FLIGQYFLYG FQVHPFYVCS RLPCPHKIDC FISRPTEKTI FLLIMYGVTG LCLLLNIWEM LHLGFGTIRD SLNSKRRELE DPGAYNYPFT WNTPSAPPGY NIAVKPDQIQ YTELSNAKIA YKQNKANTAQ EQQYGSHEEN LPADLEALQR EIRMAQERLD LAVQAYSHQN NPHGPREKKA KVGSKAGSNK STASSKSGDG KTSVWI
Explore Gap junction gamma-1 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets